Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia.

Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H.

Trends Neurosci. 2011 Aug;34(8):430-42. doi: 10.1016/j.tins.2011.05.005. Epub 2011 Jun 21.

2.

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.

Ruan Q, D'Onofrio G, Sancarlo D, Bao Z, Greco A, Yu Z.

BMC Geriatr. 2016 May 16;16:104. doi: 10.1186/s12877-016-0281-7. Review.

3.

Structural imaging in early pre-states of dementia.

Smith CD.

Biochim Biophys Acta. 2012 Mar;1822(3):317-24. doi: 10.1016/j.bbadis.2011.07.002. Epub 2011 Jul 14. Review.

4.

Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.

Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W.

Rev Bras Psiquiatr. 2013 Jul-Sep;35(3):284-94. doi: 10.1590/1516-4446-2012-3505. Review.

5.

Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.

Risacher SL, Saykin AJ.

Annu Rev Clin Psychol. 2013;9:621-48. doi: 10.1146/annurev-clinpsy-050212-185535. Epub 2013 Jan 7. Review.

6.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
7.

Advances in the early detection of Alzheimer's disease.

Nestor PJ, Scheltens P, Hodges JR.

Nat Med. 2004 Jul;10 Suppl:S34-41. Review.

PMID:
15298007
8.

[Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].

Verhey FR, Visser PJ.

Ned Tijdschr Geneeskd. 2013;157(11):A5596. Review. Dutch.

PMID:
23484512
9.

Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing.

Belleville S, Fouquet C, Duchesne S, Collins DL, Hudon C.

J Alzheimers Dis. 2014;42 Suppl 4:S375-82. doi: 10.3233/JAD-141470. Review.

PMID:
25190629
10.

A critical discussion of the role of neuroimaging in mild cognitive impairment.

Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO.

Acta Neurol Scand Suppl. 2003;179:52-76. Review. Erratum in: Acta Neurol Scand Suppl. 2003 Jul;108(1):68.

PMID:
12603252
11.

Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease.

Ikram MK, Cheung CY, Wong TY, Chen CP.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):917-22. doi: 10.1136/jnnp-2011-301628. Epub 2012 Jun 25. Review.

PMID:
22733082
12.

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.

Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hårdemark HG, Frisoni GB.

J Alzheimers Dis. 2011;26 Suppl 3:159-99. doi: 10.3233/JAD-2011-0043. Review.

PMID:
21971460
13.

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.

Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H.

Alzheimers Dement. 2014 May;10(3):381-92. doi: 10.1016/j.jalz.2013.04.506. Epub 2013 Jul 11. Review.

PMID:
23850330
14.

Proton MRS in mild cognitive impairment.

Kantarci K.

J Magn Reson Imaging. 2013 Apr;37(4):770-7. doi: 10.1002/jmri.23800. Review.

15.

Diagnosis and biomarkers of predementia in Alzheimer's disease.

Forlenza OV, Diniz BS, Gattaz WF.

BMC Med. 2010 Dec 22;8:89. doi: 10.1186/1741-7015-8-89. Review.

16.

Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment.

Apostolova LG, Thompson PM.

Neuropsychologia. 2008;46(6):1597-612. doi: 10.1016/j.neuropsychologia.2007.10.026. Epub 2007 Dec 14. Review.

17.

Mild cognitive impairment: conceptual issues and structural and functional brain correlates.

Saykin AJ, Wishart HA.

Semin Clin Neuropsychiatry. 2003 Jan;8(1):12-30. Review.

PMID:
12567329
18.

Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.

Fennema-Notestine C, McEvoy LK, Hagler DJ Jr, Jacobson MW, Dale AM; The Alzheimer's Disease Neuroimaging Initiative.

Behav Neurol. 2009;21(1):3-12. doi: 10.3233/BEN-2009-0230. Review.

19.

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202. Review.

PMID:
26402088
20.

Alzheimer's disease: Unique markers for diagnosis & new treatment modalities.

Aggarwal NT, Shah RC, Bennett DA.

Indian J Med Res. 2015 Oct;142(4):369-82. doi: 10.4103/0971-5916.169193. Review.

Supplemental Content

Support Center